Senzime AB (publ) (SNZZF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Senzime AB (publ) (SNZZF) Healthcare & Pipeline Overview

Senzime AB (publ) is a Swedish medical device company specializing in patient monitoring systems for surgical patients under anesthesia. Their flagship TetraGraph system offers neuromuscular blockade monitoring, aiming to reduce postoperative complications. The company operates in Europe, Oceania, Asia, Canada, and the United States, with a strategic partnership with Masimo.

What Is the Investment Thesis for SNZZF?

Senzime AB (publ) presents a focused investment opportunity within the medical device sector, specifically in patient monitoring. The company's TetraGraph system addresses a critical need for improved neuromuscular blockade management during surgery, potentially reducing postoperative complications and improving patient outcomes. A key value driver is the ongoing adoption of TetraGraph in hospitals globally. The strategic partnership with Masimo, integrating TetraGraph with Masimo's Root monitoring system, could accelerate market penetration. However, the company's negative profit margin of -132.1% indicates financial challenges. Upcoming catalysts include further expansion into the US market and potential new product launches. Investors should monitor revenue growth and progress towards profitability.

Based on FMP financials and quantitative analysis

SNZZF Key Highlights

• Market capitalization of $74.4M indicates a small-cap company with potential for growth.
• Negative P/E ratio of -5.09 reflects current unprofitability, requiring close monitoring of future earnings.
• Gross margin of 31.6% demonstrates some ability to generate profit from sales, but needs improvement to achieve overall profitability.
• Beta of 0.29 suggests the stock is significantly less volatile than the overall market.
• Strategic partnership with Masimo provides access to a broader customer base and distribution network.

Who Are SNZZF's Competitors?

SNZZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SNZZF's Key Strengths?

• Innovative TetraGraph technology for neuromuscular monitoring.
• Strategic partnership with Masimo.
• Established presence in Europe.
• Regulatory approvals in key markets.

What Are SNZZF's Weaknesses?

• Negative profit margin.
• Limited financial resources compared to larger competitors.
• Reliance on a single core product (TetraGraph).
• Small market capitalization.

What Could Drive SNZZF Stock Higher?

• Potential expansion into new geographic markets, such as emerging economies.
• Continued adoption of the TetraGraph system in hospitals and surgical centers.
• Strategic partnership with Masimo driving increased sales and market reach.
• Potential new product launches or enhancements to the TetraGraph system.
• Increasing awareness of the benefits of neuromuscular monitoring in reducing postoperative complications.

What Are the Key Risks for SNZZF?

• Negative return on equity (-38.3%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Competition from larger, more established medical device companies.
• Negative profit margin and limited financial resources.
• Technological obsolescence of the TetraGraph system.
• Changes in regulatory requirements impacting the approval or use of Senzime's products.
• Dependence on a single core product (TetraGraph).

What Are the Growth Opportunities for SNZZF?

• Expansion in the United States: The US market represents a significant growth opportunity for Senzime, driven by the increasing adoption of advanced patient monitoring technologies. Senzime can leverage its partnership with Masimo to accelerate market penetration and establish a strong presence in key hospitals and surgical centers. Successful expansion in the US could significantly boost revenue growth within the next 3-5 years.
• Strategic Partnerships and Acquisitions: Senzime can pursue strategic partnerships with other medical device companies or consider targeted acquisitions to expand its product portfolio and geographic reach. Collaborations with companies specializing in related areas, such as anesthesia delivery systems or postoperative care, could create synergistic opportunities and enhance Senzime's competitive position. These partnerships could materialize within the next 2-3 years.
• New Product Development: Senzime can invest in research and development to expand its product line and address unmet needs in patient monitoring. The development of new sensors, monitoring algorithms, or data analytics tools could enhance the capabilities of the TetraGraph system and attract new customers. New products could be launched within the next 3-5 years, driving revenue growth and market share gains.
• Penetration of the European Market: Senzime has an established presence in Europe, but there is still room for further market penetration. The company can focus on expanding its sales and marketing efforts in key European countries, targeting hospitals and surgical centers that have not yet adopted the TetraGraph system. Increased penetration in Europe could contribute to steady revenue growth over the next 2-3 years.
• Integration with Electronic Health Records (EHR) Systems: Senzime can enhance the value proposition of the TetraGraph system by integrating it with EHR systems. Seamless integration with EHRs would allow for automated data capture, improved data analysis, and enhanced clinical decision-making. This integration could attract new customers and strengthen Senzime's competitive advantage. Integration efforts could be completed within the next 1-2 years.

What Opportunities Does SNZZF Have?

• Expansion in the United States.
• Strategic partnerships and acquisitions.
• New product development.
• Integration with Electronic Health Records (EHR) systems.

What Threats Does SNZZF Face?

• Competition from larger, more established medical device companies.
• Technological obsolescence.
• Changes in regulatory requirements.
• Economic downturns.

What Are SNZZF's Competitive Advantages?

• Proprietary Technology: The TetraGraph system is based on patented technology that provides a competitive advantage in neuromuscular monitoring.
• Strategic Partnerships: The partnership with Masimo provides access to a broader customer base and distribution network.
• Established Brand Reputation: Senzime has established a reputation for innovation and quality in the patient monitoring market.
• Regulatory Approvals: Senzime's products have received regulatory approvals in key markets, such as Europe and the United States, creating a barrier to entry for competitors.

What Does SNZZF Do?

Senzime AB (publ) was founded in 1999 and is headquartered in Uppsala, Sweden. The company focuses on developing and marketing innovative patient monitoring solutions, primarily for use in surgical settings. Their core product, the TetraGraph system, is designed to monitor neuromuscular function in patients receiving neuromuscular blocking agents during anesthesia. This technology helps clinicians ensure optimal muscle relaxation during surgery and facilitates faster, safer recovery post-surgery by minimizing residual neuromuscular blockade. Senzime's product portfolio includes the TetraGraph monitor, TetraSens electrode array, TetraConnect data management portal, and TetraGraph Device Connectivity solutions. These products work together to provide comprehensive neuromuscular monitoring and data management capabilities. The company also develops the CliniSenz Analyzer for postoperative and continuous patient monitoring, and the Onzurf Probe for continuous sampling from gastro-intestinal organs. Senzime has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module, enhancing the integration of their technology with existing patient monitoring systems. Senzime distributes its products across Europe, Oceania, Asia, Canada, and the United States.

What Products and Services Does SNZZF Offer?

• Develops and markets the TetraGraph system for neuromuscular monitoring during surgery.
• Offers the TetraSens electrode array for stimulating and recording muscle function.
• Provides the TetraConnect data management portal for accessing and exporting data records.
• Offers TetraGraph Device Connectivity solutions for transferring data to patient monitoring systems.
• Develops the CliniSenz Analyzer for postoperative patient monitoring.
• Creates the Onzurf Probe for continuous sampling from gastro-intestinal organs.
• Partners with Masimo to integrate TetraGraph with their Root monitoring system.

How Does SNZZF Make Money?

• Sells the TetraGraph system and related consumables (e.g., TetraSens electrodes) to hospitals and surgical centers.
• Generates revenue through service and maintenance contracts for the TetraGraph system.
• Partners with Masimo to distribute the TetraGraph Smart Cable Module, sharing revenue based on sales.
• Potentially generates revenue from licensing its technology to other medical device companies.

What Industry Does SNZZF Operate In?

Senzime AB (publ) operates within the medical device industry, which is characterized by continuous innovation and increasing demand for advanced patient monitoring solutions. The global market for patient monitoring devices is projected to grow, driven by factors such as an aging population, rising prevalence of chronic diseases, and increasing adoption of minimally invasive surgical procedures. Senzime competes with larger, more established medical device companies like Koninklijke Philips (KNTPF) and Masimo (though they also have a partnership). The company's focus on neuromuscular monitoring provides a niche market opportunity, but it must effectively compete on product performance, cost, and distribution to gain market share.

Who Are SNZZF's Key Customers?

• Hospitals and surgical centers that perform procedures requiring neuromuscular blockade.
• Anesthesiologists and surgeons who use the TetraGraph system to monitor patients.
• Intensive care units utilizing CliniSenz Analyzer for post-operative monitoring.
• Research institutions using Onzurf Probe for gastro-intestinal studies.

Senzime AB (publ) Financial Trajectory

Senzime AB (publ) (SNZZF) reported $23.2M in revenue for Q1 2026, a decline of 17.8% compared to the prior quarter. The company recorded a net loss of $22.5M, with diluted EPS of $-0.14. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, SNZZF averaged $-0.20 in diluted EPS.

Company Profile

Senzime AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Uppsala, SE. The company is led by CEO Philip Siberg. SNZZF has traded publicly since 2017.

How Senzime AB (publ) Is Valued

Senzime AB (publ) carries a market capitalization of $74.4M, placing it in the micro-cap category. Relative to its peer group, SNZZF's quantitative score of 59/100 is roughly in line with the peer average of 49/100.

ROE -38%Key Financial Metrics

Return on equity for Senzime AB (publ) stands at -38.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -20.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Senzime AB (publ)'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.93 places it in the grey zone, a middle ground that warrants monitoring.

0/8 beatsEarnings Track Record

Senzime AB (publ) has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 37.9% below estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Senzime AB (publ) revenue of about $127.3M for fiscal 2026, with EPS near $-0.20.

SNZZF Financials

SNZZF Latest News

No recent news available for SNZZF.

SNZZF Analyst Consensus

SNZZF MoonshotScore

What Investors Ask About Senzime AB (publ) (SNZZF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources